Search Results - Huang, Funan
- Showing 1 - 5 results of 5
-
1
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects by Huang, Funan, Ajavon, Antoinette, Huang, Erya, Lettieri, John, Liu, Rong, Peña, Carol, Berse, Matthias
Published 2017Text -
2
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment by Zurth, Christian, Nykänen, Pirjo, Wilkinson, Gary, Taavitsainen, Päivi, Vuorela, Annamari, Huang, Funan, Reschke, Susanne, Koskinen, Mikko
Published 2021Text -
3
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors by Weekes, Colin, Lockhart, A. Craig, Lee, James J., Sturm, Isrid, Cleton, Adriaan, Huang, Funan, Lenz, Heinz‐Josef
Published 2019Text -
4
Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer by Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Published 2019Text -
5
Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer by Wong, Selina K., Chu, Quincy S.C., Spratlin, Jennifer L., Sangha, Randeep, McEwan, Alexander J.B., Morrish, Donald W., Arndt, Diane, Sergenson, Gwen, Cleton, Adriaan, Huang, Funan, Sawyer, Michael B.
Published 2019Text